Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
McKesson
Colorcon
Harvard Business School
AstraZeneca

Last Updated: January 22, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Fruquintinib

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Fruquintinib?

Fruquintinib is an investigational drug.

There have been 19 clinical trials for Fruquintinib. The most recent clinical trial was a Phase 2 trial, which was initiated on April 20th 2019.

The most common disease conditions in clinical trials are Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, and Lung Neoplasms. The leading clinical trial sponsors are Hutchison Medipharma Limited, Fudan University, and Sun Yat-sen University.

There are three US patents protecting this investigational drug and twenty-eight international patents.

Recent Clinical Trials for Fruquintinib
TitleSponsorPhase
Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract AdenocarcinomaSichuan UniversityPhase 2
Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal CancerChinese PLA General HospitalPhase 2
Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib in the Treatment of Relapsed or Metastatic NSCLC With EGFR-sensitive MutationHutchison Medipharma LimitedPhase 1

See all Fruquintinib clinical trials

Clinical Trial Summary for Fruquintinib

Top disease conditions for Fruquintinib
Top clinical trial sponsors for Fruquintinib

See all Fruquintinib clinical trials

US Patents for Fruquintinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Fruquintinib   Start Trial Substituted quinazoline compounds and their use in treating angiogenesis-related diseases Hutchison MediPharma Enterprises Limited (BS)   Start Trial
Fruquintinib   Start Trial Use of substituted quinazoline compounds in treating angiogenesis-related diseases Hutchison Medipharma Enterprises Limited (Nassau, BS)   Start Trial
Fruquintinib   Start Trial Use of substituted quinazoline compounds in treating age-related macular degeneration Hutchison Medipharma Enterprises Limited (Nassau, BS)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Fruquintinib

Drugname Country Document Number Estimated Expiration Related US Patent
Fruquintinib Australia 2009244130 2028-05-09   Start Trial
Fruquintinib Brazil PI0908675 2028-05-09   Start Trial
Fruquintinib Canada 2723148 2028-05-09   Start Trial
Fruquintinib Cyprus 1117222 2028-05-09   Start Trial
Fruquintinib Denmark 2297115 2028-05-09   Start Trial
Fruquintinib European Patent Office 2297115 2028-05-09   Start Trial
Fruquintinib Spain 2550245 2028-05-09   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Boehringer Ingelheim
Colorcon
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.